GNCAQ (Genocea Biosciences) Long-Term Debt : $2.95 Mil (As of Mar. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Genocea Biosciences Long-Term Debt?

Genocea Biosciences's Long-Term Debt for the quarter that ended in Mar. 2022 was $2.95 Mil.

Genocea Biosciences's quarterly Long-Term Debt declined from Sep. 2021 ($5.33 Mil) to Dec. 2021 ($4.15 Mil) and declined from Dec. 2021 ($4.15 Mil) to Mar. 2022 ($2.95 Mil).

Genocea Biosciences's annual Long-Term Debt declined from Dec. 2019 ($13.41 Mil) to Dec. 2020 ($0.00 Mil) but then increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($4.15 Mil).

Genocea Biosciences Long-Term Debt Historical Data

The historical data trend for Genocea Biosciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Long-Term Debt Chart

Genocea Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Long-Term Debt

Get a 7-Day Free Trial

7.65

9.57

13.41

4.15

Genocea Biosciences Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Long-Term Debt	Get a 7-Day Free Trial															7.65	6.49	5.33	4.15	2.95

Genocea Biosciences (OTCPK:GNCAQ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Genocea Biosciences Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genocea Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GNCAQ) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.genocea.com

Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.

Executives

Jacquelyn L Sumer	officer: CHIEF LEGAL & COMPLIANCE OFF	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
William D Clark	director, officer: President and CEO	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
George Siber	director	2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023
Diantha Duvall	officer: CHIEF FINANCIAL OFFICER	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Scott D Sandell	10 percent owner
Stapleton Raymond D Jr	officer: EVP PHARM SCI & MFG	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jessica Baker Flechtner	officer: VP of Research	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815